AMRX ▲ +2.0% - Amneal Pharmaceuticals, Inc. $AMRX - Amneal Announces FDA Approval and Launch of Lanreotide Injection Amneal Pharmaceuticals rose 2.0% after announcing FDA approval and commercial launch of Lanreotide Injection, a long-acting somatostatin analog used to treat acromegaly and neuroendocrine tumors. The approval expands Amneal's specialty pharmaceutical portfolio and positions the company to capture market share in the lanreotide market. 18-SEP-2026 04:01 PM ET